AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.54 USD
+0.67 (0.87%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $77.51 -0.03 (-0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for AstraZeneca PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 6,899.00 | 2,501.00 | -265.00 | 3,916.00 | 1,548.00 |
Depreciation/Amortization & Depletion | 5,387.00 | 5,480.00 | 6,530.00 | 3,149.00 | 3,762.00 |
Net Change from Assets/Liabilities | 300.00 | 3,757.00 | 2,021.00 | 361.00 | -346.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -2,241.00 | -1,930.00 | -2,323.00 | -2,627.00 | -1,995.00 |
Net Cash From Operating Activities | 10,345.00 | 9,808.00 | 5,963.00 | 4,799.00 | 2,969.00 |
Property & Equipment | -1,229.00 | -809.00 | -1,078.00 | -855.00 | -942.00 |
Acquisition/ Disposition of Subsidiaries | -189.00 | -48.00 | -9,906.00 | -822.00 | -709.00 |
Investments | -87.00 | -117.00 | 697.00 | 2,007.00 | 199.00 |
Other Investing Activities | -2,559.00 | -1,986.00 | -771.00 | -615.00 | 795.00 |
Net Cash from Investing Activities | -4,064.00 | -2,960.00 | -11,058.00 | -285.00 | -657.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 33.00 | 29.00 | 29.00 | 30.00 | 3,525.00 |
Issuance (Repayment) of Debt | -1,126.00 | -1,271.00 | 8,170.00 | 1,359.00 | -1,000.00 |
Increase (Decrease) Short-Term Debt | -107.00 | -170.00 | -516.00 | 81.00 | -702.00 |
Payment of Dividends & Other Distributions | -4,481.00 | -4,364.00 | -3,856.00 | -3,572.00 | -3,592.00 |
Other Financing Activities | -886.00 | -1,047.00 | -178.00 | -101.00 | 4.00 |
Net Cash from Financing Activities | -6,567.00 | -6,823.00 | 3,649.00 | -2,203.00 | -1,765.00 |
Effect of Exchange Rate Changes | -60.00 | -80.00 | -62.00 | 12.00 | 5.00 |
Net Change In Cash & Equivalents | -346.00 | -55.00 | -1,508.00 | 2,323.00 | 552.00 |
Cash at Beginning of Period | 5,983.00 | 6,038.00 | 7,546.00 | 5,223.00 | 4,671.00 |
Cash at End of Period | 5,637.00 | 5,983.00 | 6,038.00 | 7,546.00 | 5,223.00 |
Diluted Net EPS | 1.91 | 1.06 | 0.04 | 1.22 | 0.52 |
Fiscal Year End for AstraZeneca PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 5,197.00 | 2,800.00 | 6,899.00 | 6,002.00 | 4,350.00 |
Depreciation/Amortization & Depletion | 2,534.00 | 1,255.00 | 5,387.00 | 4,060.00 | 2,778.00 |
Net Change from Assets/Liabilities | -584.00 | -455.00 | 300.00 | 150.00 | -747.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -1,576.00 | -1,114.00 | -2,241.00 | -2,247.00 | -1,530.00 |
Net Cash From Operating Activities | 5,571.00 | 2,486.00 | 10,345.00 | 7,965.00 | 4,851.00 |
Property & Equipment | -746.00 | -364.00 | -1,229.00 | -705.00 | -391.00 |
Acquisition/ Disposition of Subsidiaries | -3,245.00 | -948.00 | -189.00 | -799.00 | -587.00 |
Investments | -101.00 | -81.00 | -87.00 | -89.00 | 74.00 |
Other Investing Activities | -1,193.00 | -1,020.00 | -2,559.00 | -1,394.00 | -862.00 |
Net Cash from Investing Activities | -5,285.00 | -2,413.00 | -4,064.00 | -2,987.00 | -1,766.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 11.00 | 6.00 | 33.00 | 12.00 | 8.00 |
Issuance (Repayment) of Debt | 2,333.00 | 4,969.00 | -1,126.00 | -839.00 | 408.00 |
Increase (Decrease) Short-Term Debt | 2,353.00 | 927.00 | -107.00 | -84.00 | -57.00 |
Payment of Dividends & Other Distributions | -3,050.00 | -3,033.00 | -4,481.00 | -4,479.00 | -3,069.00 |
Other Financing Activities | -841.00 | -841.00 | -886.00 | -886.00 | -840.00 |
Net Cash from Financing Activities | 806.00 | 2,028.00 | -6,567.00 | -6,276.00 | -3,550.00 |
Effect of Exchange Rate Changes | -52.00 | -46.00 | -60.00 | -66.00 | -47.00 |
Net Change In Cash & Equivalents | 1,040.00 | 2,055.00 | -346.00 | -1,364.00 | -512.00 |
Cash at Beginning of Period | 5,637.00 | 5,637.00 | 5,983.00 | 5,983.00 | 5,983.00 |
Cash at End of Period | 6,677.00 | 7,692.00 | 5,637.00 | 4,619.00 | 5,471.00 |
Diluted Net EPS | 0.62 | 0.70 | 0.30 | 0.44 | 0.58 |